Third Quarter 2025 Financial Results November 5, 2025 Cautionary Note Regarding Forward-Looking Statements Unless otherwise noted, all references in this presentation to net income (loss), net income (loss) per share, adjusted operating income (loss) and adjusted operating income (loss) per share should be read as net income (loss) income (loss) available to Enact's common stockholders per diluted share, respectively. 2 1 U.S. Generally Accepted Accounting Principles Third Quarter Key Takeaways Insurance in ...

Unlocking value through digital and Al leadership Lloyds Banking Group 6 November 2025 Introduction Charlie Nunn Welcome and introduction Our strategic seminar series Charlie Nunn Group Chief Executive October 2023: Deepen and innovate in Consumer November 2023: Develop our Corporate & Institutional business March 2024: Broaden our Mass Affluent and IP&I offering June 2024: Digitise and diversify our BCB business November 2025: Unlocking value through digital and Al leadership Today's presenters Ron van Kem ...

Anaphylm (dibutepinephrine) Sublingual Film - The FDA confirmed that it will not require an Advisory Committee to review the Company's New Drug Application for Anaphylm[8] - The company is preparing for a U S launch in Q1 2026, if approved by the FDA[8] - The company broadened the patent estate for Anaphylm with the issuance of two new patents, extending patent protection into 2037[8] AQST-108 and AdrenaVerse Platform - The company plans to open Investigational New Drug application for AQST-108 with FDA in Q4 2025[11] - The company expects to initiate a clinical study for AQST-108 for Alopecia Areata in 1H 2026[11] Financial Position - The company successfully completed an equity raise of $85 million in August 2025[11] - The company also completed a strategic financing for $75 million with RTW Investments, LP, subject to FDA approval of Anaphylm and refinancing of the Company's existing debt[11] - The company's ending cash balance in Q3 2025 was $129.1 million[17] - The company expects to meet near-term milestones with projected cash runway into 2027[16] - The company's 2025 outlook includes total revenues of approximately $44-$50 million and a non-GAAP adjusted EBITDA loss of approximately $47-$51 million[23]

Unlocking Long-Term Growth through our Infrastructure, Expertise and Partnerships C o r p o r a t e D e c k | N o v e m b e r 6 , 2 0 2 5 Disclaimer This presentation contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of our future financial and operating performance and growth plans, taking into account the information currently available to us. These statements are not statem ...

Third Quarter Financial Results NOVEMBER 5, 2025 Mike Thomson Chief Executive Officer & President Deb McCann Chief Financial Officer Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Unisys cautions readers that the assumptions forming the basis for forward-looking state ...

Warintza PFS Highlights - PFS confirms Warintza's status as a Tier 1 project[23] - Measured and Indicated Mineral Resources increased by 312% compared to the 2024 MRE[24] - Average annual copper equivalent production is projected to be 304kt for the first 5 years and 242kt for the first 15 years[24] - The project boasts a reserve life of over 20 years with a low LOM strip ratio of 053:1[24] - First quartile AISC is estimated at $085/lb for the first 5 years and $107/lb for the first 15 years[24] - The post-tax NPV8% is $46 billion with a post-tax IRR of 26% and a payback period of 26 years[24] Resource Base and Production Scale - Total Reserves are 5,294 kt of Copper Equivalent[32] - Total Measured and Indicated Resources are 11,820 kt of Copper Equivalent[32] Financials - Average annual EBITDA is projected to be $19 billion for the first 5 years and $14 billion for the first 15 years[24] - Average annual post-tax Free Cash Flow is projected to be $13 billion for the first 5 years and $10 billion for the first 15 years[24]

November 6, 2025 Q3 2025 Results Clinical Trial Appendix Disclosures Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeOne's research, discovery, pre-clinical and clinical programs and plans. Actual results may differ materially from those indicated in the forward- l ...

Financial Performance - Net sales reached $3.072 billion, a 7% increase compared to the previous year[65] - Organic sales grew by 6%, driven by electronics, healthcare, water, and industrials end-markets[14] - Operating EBITDA increased by 6% year-over-year to $840 million, attributed to organic growth and productivity[15] - Adjusted EPS remained consistent at $1.09 per share, with higher segment earnings offset by a higher tax rate[15] - Transaction-adjusted free cash flow from continuing operations was $576 million, representing a 126% conversion rate[15] Business Segments - IndustrialsCo's organic sales increased by 4%[15] - ElectronicsCo's organic sales increased by 10%[15] - Healthcare & Water Technologies sales increased by high-single digits organically[21] - Diversified Industrials sales increased by low-single digits organically[21] Strategic Initiatives - DuPont completed the spin-off of its Electronics business, Qnity, on November 1, 2025[3] - A definitive agreement was reached to sell the aramids business to TJC LP for approximately $1.2 billion in cash, a $300 million note, and a minority equity interest valued at $325 million[4] - A $2 billion share repurchase authorization was announced, with an initial $500 million accelerated share repurchase (ASR) expected to launch quickly[10] Guidance - Full-year 2025 operating EBITDA guidance was raised to approximately $1.6 billion[28] - Full-year 2025 net sales are projected to be approximately $6.840 billion[29] - Full-year 2025 adjusted EPS is projected to be approximately $1.66[29]

THIRD QUARTER 2025 HIGHLIGHTS 1 SAFE HARBOR STATEMENT Forward Looking Statements This presentation, as well as other written or oral communications made from time to time by us, may contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements refer to our current expectations and projections relating to our financial condition, results of operations, plans, objectives, strategies, future performance, and business. All sta ...

Financial Performance - Adjusted EBITDA reached $695 million, demonstrating a year-over-year growth of 18.7%[68] - The Adjusted EBITDA margin hit a record 48.9%[18,68] - Equity Free Cash Flow (EFCF) for the first 9 months of 2025 was $638 million, an increase of $98 million compared to the same period in 2024[17,70,73] - Service revenue increased to $1344 million, a 0.5% increase compared to Q3 2024[68] Customer Growth - Postpaid net additions reached 293,000[17] - Home net additions totaled 60,000[18] - Mobile postpaid customers grew by 14% year-over-year[21] - Home HFC/FTTH customers increased by 5.4% year-over-year[25] Strategic Initiatives - Millicom incorporated Ecuador and Uruguay, diversifying its LATAM footprint[53] - Revenue from Ecuador is $489 million and Adjusted EBITDA is $161 million[54] - Revenue from Uruguay is $246 million and Adjusted EBITDA is $93 million[56] Financial Position - Net debt stood at $4627 million[90,115] - Leverage ratio decreased to 2.09x[18,90,115] Country-Specific Performance - Colombia's Adjusted EBITDA margin increased by 4.9 percentage points[35] - Guatemala's mobile service revenue grew by 20% in local currency[41] - Panama achieved a record Adjusted EBITDA margin of 52.2%[49,51]